Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas
- 2 March 2012
- journal article
- laboratory investigation
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 108 (3), 395-402
- https://doi.org/10.1007/s11060-012-0842-3
Abstract
Despite numerous clinical trials over the past 2 decades, the overall survival for children diagnosed with diffuse intrinsic pontine glioma (DIPG) remains 9–10 months. Radiation therapy is the only treatment with proven effect and novel therapies are needed. Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the epidermal growth factor receptor and is expressed in many tumor types but is rarely found in normal tissue. A peptide vaccine targeting EGFRvIII is currently undergoing investigation in phase 3 clinical trials for the treatment of newly diagnosed glioblastoma (GBM), the tumor in which this variant receptor was first discovered. In this study, we evaluated EGFRvIII expression in pediatric DIPG samples using immunohistochemistry with a double affinity purified antibody raised against the EGFRvIII peptide. Staining of pediatric DIPG histological samples revealed expression in 4 of 9 cases and the pattern of staining was consistent with what has been seen in EGFRvIII transfected cells as well as GBMs from adult trials. In addition, analysis of tumor samples collected immediately post mortem and of DIPG cells in culture by RT-PCR, western blot analysis, and flow cytometry confirmed EGFRvIII expression. We were therefore able to detect EGFRvIII expression in 6 of 11 DIPG cases. These data suggest that EGFRvIII warrants investigation as a target for these deadly pediatric tumors.Keywords
This publication has 27 references indexed in Scilit:
- Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine gliomaProceedings of the National Academy of Sciences, 2011
- Pineal Parenchymal Tumor of Intermediate DifferentiationNeurosurgery, 2010
- EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell LinesClinical Cancer Research, 2009
- Neurosphere Culture and Human Organotypic Model to Evaluate Brain Tumor Stem CellsMethods in Molecular Biology, 2009
- Genetically engineered T cells to target EGFRvIII expressing glioblastomaJournal of Neuro-Oncology, 2009
- Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant gliomaSeminars in Immunology, 2008
- Brainstem Tumors: Where Are We Today?Pediatric Neurosurgery, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Expression of constitutively activated EGFRvlll in non‐small cell lung cancerCancer Science, 2003
- Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial originNature, 1985